KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, a favorable risk/reward profile, and hedge fund interest. Despite a lack of immediate trading signals and weak financial performance, the long-term potential of its lead program KRRO-121 and recent upgrades by analysts make it an attractive investment opportunity.
The technical indicators show a bearish trend with the MACD below zero and negatively contracting, RSI in the neutral zone at 59.47, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 12.304), suggesting limited immediate upside. However, the long-term trend may improve as catalysts unfold.
Strong analyst upgrades with significant price target increases, highlighting the potential of KRRO-121 for hyperammonemia and urea cycle disorders.
Hedge fund buying activity has surged by 1445.31% over the last quarter, indicating institutional confidence.
The scientific rationale and preclinical data for KRRO-121 are compelling, with analysts viewing the risk/reward profile as favorable.
Weak financial performance in the latest quarter, with net income and EPS declining significantly YoY.
No recent news or congress trading data to provide additional support for the stock.
Bearish technical indicators suggest limited short-term momentum.
In Q3 2025, revenue remained flat YoY at $1,090,000. However, net income dropped by -13.99% YoY to -$18,061,000, and EPS declined by -15.04% YoY to -1.92. The gross margin remained stable at 100%. The financial performance reflects ongoing challenges but does not overshadow the long-term potential of the company's lead program.
Analysts have shown strong support for Korro Bio, with multiple upgrades in recent weeks. Price targets range from $15 to $30, reflecting confidence in the company's lead program KRRO-121 and its potential to address unmet medical needs. Analysts view the risk/reward profile as favorable, with significant upside potential.
